Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study

Journal of Clinical Oncology

Volumn 35, Issue 16, 2017, Pages 1795-1802

  Martinelli, Giovanni ^a   Boissel, Nicolas ^c   Chevallier, Patrice ^d   Ottmann, Oliver ^e   Gökbuget, Nicola ^g   Topp, Max S ^a   Fielding, Adele K ^f   Rambaldi, Alessandro ^b   Ritchie, Ellen K ⁱ   Papayannidis, Cristina ^h   Sterling, Lulu Ren ^j   Benjamin, Jonathan ^j   Stein, Anthony ^k  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g GOETHE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^j AMGEN INC   (United States)

^k Gehr Family Center for Leukemia Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLINATUMOMAB; CYTARABINE; DASATINIB; DEXAMETHASONE; IMATINIB; METHOTREXATE; NILOTINIB; PONATINIB; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHASIA; ARTICLE; BONE MARROW; BRAIN HEMORRHAGE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; CONSCIOUSNESS DISORDER; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMIPLEGIA; HUMAN; INFECTION; MALE; MEMORY DISORDER; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSED REFRACTORY PHILADELPHIA CHROMOSOME; REMISSION; RESPIRATORY FAILURE; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INTERRUPTION; TREMOR; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

ADULT; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 85026225911     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.3531     Document Type: Article

References (39)

1. Fielding AK: Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2011:231-237, 2011
2. Fielding AK: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: A broader range of options, improved outcomes, and more therapeutic dilemmas. Am Soc Clin Oncol Educ Book 2015:e352-e359, 2015
3. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al: Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: A GRAALL study. Biol Blood Marrow Transplant 19:150-155, 2013
4. Chalandon Y, Thomas X, Hayette S, et al: Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125:3711-3719, 2015
5. Brissot E, Labopin M, Beckers MM, et al: Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100:392-399, 2015
6. Soverini S, Colarossi S, Gnani A, et al: Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92:401-404, 2007
7. Maino E, Sancetta R, Viero P, et al: Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther 14:723-740, 2014
8. Ottmann OG, Pfeifer H: Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology (Am Soc Hematol Educ Program) 2009:371-381, 2009
9. Leoni V, Biondi A: Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica 100:295-299, 2015
10. Lilly MB, Ottmann OG, Shah NP, et al: Dasatinib 140mg once daily versus 70 mgtwice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 85:164-170, 2010
11. Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783-1796, 2013
12. Radich JP: Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15:91-103, 2002
13. Ravandi F, Jorgensen JL, Thomas DA, et al: Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122:1214-1221, 2013
14. Scheuring UJ, Pfeifer H, Wassmann B, et al: Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia 17:1700-1706, 2003
15. Miller GD, Bruno BJ, Lim CS: Resistant mutations in CML and Ph (+) ALL: Role of ponatinib. Bi ologics 8:243-254, 2014
16. Zabriskie MS, Eide CA, Tantravahi SK, et al: BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428-442, 2014
17. Deininger MW, Hodgson JG, Shah NP, et al: Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 127:703-712, 2016
18. Bargou R, Leo E, Zugmaier G, et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977, 2008
19. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 16:57-66, 2015
20. Topp MS, Gökbuget N, Zugmaier G, et al: Phase II trial of the anti-CD19 bispecific T cellengager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134-4140, 2014
21. van Rhee F, Hochhaus A, Lin F, et al: p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87:5213-5217, 1996
22. National Cancer Institute: NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Bethesda, MD, National Cancer Institute, 2014
23. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
24. Nicolini FE, Basak GW, Soverini S, et al: Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118:5697-5700, 2011
25. Soverini S, Gnani A, Colarossi S, et al: Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114:2168-2171, 2009
26. Parker WT, Yeung DT, Yeoman AL, et al: The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood 127:1870-1880, 2016
27. Ottmann OG, Larson RA, Kantarjian HM, et al: Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 27:1411-1413, 2013
28. Ottmann O, Dombret H, Martinelli G, et al: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 110:2309-2315, 2007
29. Cortes JE, Kantarjian H, Shah NP, et al: Ponatinib in refractory Philadelphia chromosomepositive leukemias. N Engl J Med 367:2075-2088, 2012
30. Kantarjian H, Stein A, Gökbuget N, et al: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Eng J Med 376:836-847, 2017
31. Cortes-Franco J, Khoury HJ, Nicolini FE, et al: Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation: Results of an ongoing multicenter phase 2/3 study. Blood 114:644, 2009 (abstr)
32. Cortes J, Talpax M, Bixby D, et al: A phase I trial (AP 24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings. Blood 116:210, 2010 (abstr)
33. Kantarjian HM, DeAngelo DJ, Stelljes M, et al: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740-753, 2016
34. Kantarjian HM, Stein AS, Bargou RC, et al: Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from two phase 2 studies. Cancer 122:2178-2185, 2016
35. Eide CA, O'Hare T: Chronic myeloid leukemia: Advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep 10:158-166, 2015
36. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008
37. Bassan R, Spinelli O, Oldani E, et al: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113:4153-4162, 2009
38. Spinelli O, Peruta B, Tosi M, et al: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 92:612-618, 2007
39. Bassan R, Spinelli O, Oldani E, et al: Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J 4:e225, 2014